Determinants of glucose toxicity and its reversibility in the pancreatic islet beta-cell line, HIT-T15.
about
Early Treatment with Basal Insulin Glargine in People with Type 2 Diabetes: Lessons from ORIGIN and Other Cardiovascular TrialsInterventions to preserve beta-cell function in the management and prevention of type 2 diabetesInsulin use early in the course of type 2 diabetes mellitus: the ORIGIN trialThe effect of early insulin therapy on pancreatic β-cell function and long-term glycemic control in newly diagnosed type 2 diabetic patientsEffects of intensive insulin therapy upon pancreatic β cell function in patients newly diagnosed with type II diabetes.Hypoglycemic and beta cell protective effects of andrographolide analogue for diabetes treatment.Does inhibition of β-cell proliferation by free fatty acid in mice explain the progressive failure of insulin secretion in type 2 diabetes?Determination of Optimal Sample Size for Quantification of β-Cell Area, Amyloid Area and β-Cell Apoptosis in Isolated Isletsβ-cell function preservation after 3.5 years of intensive diabetes therapyGlucagon-like peptide-1 triggers protective pathways in pancreatic beta-cells exposed to glycated serum.Glucolipotoxicity: fuel excess and beta-cell dysfunction.Stress-impaired transcription factor expression and insulin secretion in transplanted human islets.Failure to initiate early insulin therapy - A risk factor for diabetic retinopathy in insulin users with Type 2 diabetes mellitus: Sankara Nethralaya-Diabetic Retinopathy Epidemiology and Molecular Genetics Study (SN-DREAMS, Report number 35).Beta-cell deterioration during diabetes: what's in the gun?Early insulin treatment in type 2 diabetes: what are the pros?Genetics of new-onset diabetes after transplantation.Implication of mitochondrial cytoprotection in human islet isolation and transplantation.Nrf2/antioxidant pathway mediates β cell self-repair after damage by high-fat diet-induced oxidative stress.Immediate enhancement of first-phase insulin secretion and unchanged glucose effectiveness in patients with type 2 diabetes after Roux-en-Y gastric bypass.Bottom-up proteomics analysis of the secretome of murine islets of Langerhans in elevated glucose levels.
P2860
Q26767164-E5C847D4-9981-459F-8110-618B4948098FQ26830871-F5583225-96EF-4033-BAC8-9833EA8619D3Q27024597-CDF05068-B5BD-4EC6-9C91-5C766351B87CQ34102119-752AAB4D-C595-4647-BA37-3ABEE18A60CCQ35173918-43054E6A-9E70-49BB-BAA9-3C20C99BF717Q35575433-1000BCBE-FE5F-4626-A4D8-C9ED72A0FC24Q35766925-2FA915B0-68D2-4453-8905-D31933D5F6ADQ35932787-A2E95C14-DAB6-4CFD-AC56-E7BB16022753Q36047178-2D86B071-42B0-4D7F-8140-1B26ACB1F7C7Q36853698-8C3D1F6B-0BB4-4202-B976-D19CDA9BA288Q36861036-B0BBEB95-484F-4D27-B6E9-7AD104D31D15Q36867289-0EE29C91-96F8-4EFE-8834-7F0502F592A7Q37189508-2AD23169-99F1-41F8-AA4F-254A9EA2B7EAQ37596131-15676A54-B32A-41B4-BC69-DD738D1CE07FQ37624279-C831ECFC-E464-44A0-943E-4C7E9FCC7B12Q37733563-876B9E4D-953E-4D32-B0CB-19B443ACDD61Q41770952-9B89D4F8-901C-444F-A1E7-1D4F6159E029Q47268997-C87881EA-6C87-4B7B-9025-3F6116E5BBB4Q48231744-A22F4BE0-F535-4924-AF5B-7A6CDBA8FB6BQ50235117-A3A2FE2B-D119-4DBA-BC24-FC3011C00332
P2860
Determinants of glucose toxicity and its reversibility in the pancreatic islet beta-cell line, HIT-T15.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh
2000年學術文章
@zh-hant
name
Determinants of glucose toxici ...... islet beta-cell line, HIT-T15.
@en
type
label
Determinants of glucose toxici ...... islet beta-cell line, HIT-T15.
@en
prefLabel
Determinants of glucose toxici ...... islet beta-cell line, HIT-T15.
@en
P2093
P2860
P921
P1476
Determinants of glucose toxici ...... islet beta-cell line, HIT-T15.
@en
P2093
Gleason CE
Gonzalez M
Robertson RP
P2860
P304
P356
10.1152/AJPENDO.2000.279.5.E997
P577
2000-11-01T00:00:00Z